NasoNeb Delivery of an Intranasal Steroid

Completed · Phase 4 · Has a placebo group

Conditions studied: Perennial Allergic Rhinitis

In brief

The purpose of this study is to see if a nasal steroid drug delivered to the nose with the NasoNeb™ inhaler improves the symptoms of people with perennial allergic rhinitis (year round allergy symptoms).

Key facts

Study ID

NCT01270256

Run by

University of Chicago

People needed

41

Starts

2011-01-01

Expected to finish

2012-08-01

Last updated by the study team

2014-07-25

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males and females between 18 and 55 years of age.
• History of perennial allergic rhinitis.
• Positive skin test to dust mite, dog, cat or indoor mold antigen.
• And a combined nasal AM and PM score of ≥4 for nasal congestion in the day preceding entry and total nasal symptom score greater than 8.

You may not qualify if…

• Physical signs or symptoms suggestive of renal, hepatic or cardiovascular disease.
• Pregnant or lactating women.
• Subjects treated with systemic steroids during the previous 30 days.
• Subjects treated with topical (inhaled, intranasal or intraocular) steroids, Nasalcrom or Opticrom during the previous 30 days.
• Subjects treated with oral antihistamine/decongestants during the previous seven days.
• Subjects treated with topical (intranasal or intraocular) antihistamine/decongestants during the previous 3 days.
• Subjects treated with immunotherapy and are escalating their dose.
• Subjects on chronic anti-asthma medications.
• Subjects with polyps in the nose or a significantly displaced septum.
• Upper respiratory infection within 14 days prior to study start.

Where it is running

• University of Chicago — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.